超便携定量超声评估肝脂肪变性
本研究在超便携超声设备Hepatoscope上实现7种定量超声参数,先在体外评估可行性,再对60例慢性肝病患者以前瞻性临床研究评估其可靠性、准确性和分期能力,以受控衰减参数(CAP)为参考标准。Lizzi-Feleppa中频带拟合和衰减两个参数可靠性好(ICC分别为0.89和0.86),与CAP相关性R²分别为0.65和0.6,检测脂肪变性(S0 vs ≥S1)的AUC分别为0.90和0.86。结论认为定量超声可在超便携超声扫描仪上可靠、准确地实施,超便携性与肝脏脂肪定量评估的结合有望用于大规模筛查和监测肝脂肪变性。
要点
- 超便携设备Hepatoscope上Lizzi-Feleppa中频带拟合和衰减参数可靠(ICC分别为0.89和0.86)。
- 两参数与CAP相关性R²分别为0.65和0.6,检测脂肪变性(S0 vs ≥S1)AUC分别为0.90和0.86。
- 定量超声在超便携超声扫描仪上可可靠、准确地实施,有望用于大规模筛查和监测肝脂肪变性。
核心结论
- 定量超声可在超便携超声扫描仪上可靠、准确地实施,超便携性与肝脏脂肪定量评估的结合有望用于大规模筛查和监测肝脂肪变性。
研究设计与样本
- 前瞻性临床研究,纳入60例因已知慢性肝病转诊至肝病门诊的患者,使用新型超便携超声设备Hepatoscope采集超声信号,以受控衰减参数(CAP)为参考标准;另在体外评估Hepatoscope实施定量超声的可行性,共研究7种已建立的定量超声参数。
诊断标准与关键数值
- Lizzi-Feleppa中频带拟合可靠性ICC=0.89,与CAP的R²=0.65,检测脂肪变性(S0 vs ≥S1)AUC=0.90(95%CI 0.81-0.99)。
- 衰减参数可靠性ICC=0.86,与CAP的R²=0.6,检测脂肪变性(S0 vs ≥S1)AUC=0.86(95%CI 0.76-0.96)。
- 定量超声参数可靠性范围为中等(ICC>0.50)至优秀(ICC>0.90)。
临床应用与阅片要点
- 在超便携超声扫描仪上可使用Lizzi-Feleppa中频带拟合和衰减参数进行肝脏脂肪变性的定量评估。
- 以CAP为参考标准时,上述两参数对脂肪变性(S0 vs ≥S1)具有较高的检测准确性(AUC分别为0.90和0.86)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aimed to evaluate the performances of quantitative ultrasound (QUS) for the detection and assessment of hepatic steatosis when implemented using an ultraportable ultrasound scanner.
METHODS: Seven established QUS parameters were investigated. Ultrasound signals were acquired using a new ultraportable ultrasound device, the Hepatoscope. The feasibility of QUS using the Hepatoscope was first assessed in vitro. Clinical reliability, accuracy and staging capabilities were evaluated in 60 patients referred to a hepatology consultation for known chronic liver disease and enrolled in a prospective clinical investigation using the controlled attenuation parameter (CAP) as ground truth.
RESULTS: QUS parameters showed moderate (intra-class correlation coefficient [ICC] >0.50) to excellent (ICC >0.90) reliability. Two parameters, namely Lizzi-Feleppa mid-band fit and attenuation, were both reliable (ICC = 0.89 and 0.86, respectively) and correlated with the CAP (squared Pearson correlation coefficient of R2 = 0.65 and R2 = 0.6, respectively). For steatosis detection (S0 vs. ≥S1), the two parameters yielded an area under the receiving operating characteristic curve of 0.90 and 0.86, respectively (95% confidence interval: [0.81-0.99] and [0.76-0.96], respectively).
CONCLUSION: QUS can be reliably and accurately implemented on ultraportable ultrasound scanners. The combination of ultraportability and quantitative assessment of liver fat is promising for large-scale screening and monitoring of hepatic steatosis.
引用
- Hériard-Dubreuil B, Besson A, Mamou J, et al. Ultraportable Quantitative Ultrasound for Hepatic Steatosis Assessment. Ultrasound Med Biol. 2024. PMID: 39317626. doi:10.1016/j.ultrasmedbio.2024.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。